This Article Full Text Full Text (PDF) All Versions of this Article: 37/6/1539    most recent 01.STR.0000221783.08037.a9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watanabe, T. Articles by Urabe, T. Search for Related Content PubMed PubMed Citation Articles by Watanabe, T. Articles by Urabe, T. Related Collections Animal models of human disease Apoptosis Platelet function inhibitors Neuroprotectors

(Stroke. 2006;37:1539.)
© 2006 American Heart Association, Inc.

Original Contributions

Cilostazol Protects Against Brain White Matter Damage and Cognitive Impairment in a Rat Model of Chronic Cerebral Hypoperfusion

Terubumi Watanabe, MD; Ning Zhang, MD; Meizi Liu, MD; Ryota Tanaka, MD, PhD; Yoshikuni Mizuno, MD, PhD Takao Urabe, MD, PhD

From the Department of Neurology (T.W., N.Z., M.L., R.T., Y.M., T.U.) and Research Institute for Disease of Old Age (Y.M.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.

Correspondence to Takao Urabe, MD, PhD, Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. E-mail t_urabe{at}med.juntendo.ac.jp

Background and Purpose— White matter lesions contribute to cognitive impairment in poststroke patients. The present study was designed to assess the neuroprotective mechanisms of cilostazol, a potent inhibitor of type III phosphodiesterase, through signaling pathways that lead to activation of transcription factor cAMP-responsive element binding protein (CREB) phosphorylation using rat chronic cerebral hypoperfusion model.

Methods— Rats underwent bilateral common carotid artery ligation. They were divided into the cilostazol group (n=80) and the vehicle (control) group (n=80). Performance at the Morris water maze task and immunohistochemistry for 4-hydroxy-2-nonenal (HNE), glutathione-S-transferase-pi (GST-pi), ionized calcium-binding adaptor molecule 1, phosphorylated CREB (p-CREB), Bcl-2, and cyclooxygenase-2 (COX-2) were analyzed at baseline and at 3, 7, 14, 21, and 28 days after hypoperfusion.

Result— Cilostazol significantly improved spatial learning memory (6.8±2.3 seconds; P<0.05) at 7 days after hypoperfusion. Cilostazol markedly suppressed accumulation of HNE-modified protein and loss of GST-pi–positive oligodendrocytes in the cerebral white matter during the early period after hypoperfusion (P<0.05). Cilostazol upregulated p-CREB and Bcl-2 (P<0.05), increased COX-2 expression, and reduced microglial activation in the early period of hypoperfusion.

Conclusion— Our results indicate that cilostazol exerts a brain-protective effect through the CREB phosphorylation pathway leading to upregulation of Bcl-2 and COX-2 expressions and suggest that cilostazol is potentially useful for the treatment of cognitive impairment in poststroke patients.

Key Words: apoptosis • neuroprotection • white matter

This article has been cited by other articles:

				Y. Peng, S. Xu, G. Chen, L. Wang, Y. Feng, and X. Wang l-3-n-Butylphthalide Improves Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 902 - 910. [Abstract] [Full Text] [PDF]